HCPCS Code J1932: Injection, Lanreotide, (Cipla), 1 mg

HCPCS code J1932 covers the injection of lanreotide (Cipla) 1 mg for billing, documentation, and reimbursement under Medicare and CMS guidelines.

Use Code

## **What is HCPCS Code J1932?** HCPCS code J1932 refers to the injection of lanreotide at a dose of 1 mg. The official CMS code descriptor includes the notation '(cipla)' to identify the specific drug product formulation, but this naming convention in the descriptor does not imply exclusive manufacturer specificity in most clinical or payer billing contexts. Instead, J1932 is used to distinguish this lanreotide injectable formulation from other forms, such as J1930, which is designated for the Somatuline Depot® branded formulation. This code is part of the HCPCS Level II coding system, maintained by CMS. Its effective date was on October 1, 2022, to uniformly identify injectable drugs by their drug name and dose for billing and claims processing. Lanreotide works as a medication used for certain medical treatments that require injection. The code J1932 is used for billing and claims processing to represent the administration of this specific drug dose. CMS established the code to enable accurate reporting, payment, and documentation of services involving lanreotide injection. The coding system ensures uniformity across healthcare providers and insurance programs for consistent claims handling. It is important to note that while the code identifies the drug and dose, coverage and payment decisions depend on the payer's policies.

## **HCPCS code J1932 documentation requirements** HCPCS code J1932, which is for the injection of lanreotide (Cipla) 1 mg, follows the general documentation requirements applicable to drugs administered by injection under Medicare and CMS guidelines. Documentation must include: Clear evidence in the medical record of the medical necessity of the drug administration. - Detailed records of the drug dosage, route of administration, and date of service. - Physician or qualified healthcare provider's order specifying the medication and dose. - Documentation supporting the diagnosis or condition for which the drug was prescribed. - Any additional documentation required by payer policies or local coverage determinations (LCDs). CMS does not specify unique documentation requirements exclusively for J1932, but adherence to Medicare's general drug administration documentation standards applies. This includes having a proper written order, accurate medical record entries that support the necessity and administration of the medication, and adhering to local and national payer policies for injectable drugs. Documentation may also be reviewed for coding accuracy and medical necessity during audits or claims review. Providers should ensure all these elements are in place to comply with CMS and payer rules for billing J1932.

## **J1932 billing requirements** The billing requirements for HCPCS code J1932 (injection, lanreotide, Cipla, 1 mg) include: - Use accurate coding reflecting the administration of 1 mg lanreotide. - Bill in units corresponding exactly to the amount administered, as CMS assigns dose descriptors in the smallest billable unit to enable multiple-unit billing if needed. - Include modifiers where applicable, especially JW and JZ modifiers for discarded drugs and single-dose vial policy adherence under CMS guidelines. - Submit detailed documentation supporting the medical necessity of the injection, dosage, and date of administration in claims. - Include relevant diagnosis codes that justify the drug's use. - Follow payer-specific coverage, payment policies, and local coverage determinations (LCDs). - Report 1 unit per 1 mg of drug administered on the claim. - Ensure compliance with Medicare billing rules for injectable drugs, including any special instructions by CMS for the drug’s payment methodology. - Use the appropriate revenue codes and complete all required claim fields accurately. These billing protocols are designed to ensure proper reimbursement, regulatory compliance, and audit readiness for J1932 administration.

## **Other relevant codes** Other relevant HCPCS codes related to J1932 (Injection, lanreotide, Cipla, 1 mg) include: - **J1930**: Injection, lanreotide, 1 mg, used for Somatuline Depot®, the brand version of lanreotide. - **J1931**: Injection, laronidase, 0.1 mg, although a different drug, it is numerically close and part of the same drugs administered by injection range. - **J1938**: Injection, furosemide, up to 20 mg, another injectable drug code in the range often listed alongside J1932. Additionally, other drugs in the same functional category, such as somatostatin analogs, may have their own HCPCS codes like: - **J2353**: Injection, octreotide, depot form (another somatostatin analog).

Frequently asked questions

J1932 is used for the injection of lanreotide (Cipla), mainly indicated for treating acromegaly and neuroendocrine tumors by regulating hormone levels in the body with a synthetic somatostatin analog.

The J code for pemetrexed is J9305 (Injection, pemetrexed, 10 mg)[general knowledge confirmed by CMS patterns].

The J code for lanreotide injection depends on the brand: J1930 for Somatuline Depot (lanreotide) and J1932 for Cipla's lanreotide injection (1 mg).

J1930 is for Somatuline Depot (lanreotide), while J1932 is specifically for Cipla's lanreotide injection. Both represent lanreotide but are distinct codes due to different manufacturers and FDA approvals, ensuring accurate coding and reimbursement.